About Psylo
Psylo is a Healthcare company based in Sydney (Australia) founded in 2021 by Josh Ismin and Sam Banister. Psychedelic-derived therapeutics for mental illnesses are developed. Psylo has raised $14.18 million across 3 funding rounds from investors including Focalpoint Partners, Main Sequence and Lionheart Ventures. Its chief executive, as recorded, is Josh Ismin. Psylo offers products and services including Neuroplastogen Therapies and Pipeline Therapies. Its focus areas include Life Sciences, Neurology, Drugs and Psychiatric. Its legal entity is PSYLO PTY LTD.
Company details
Psylo was founded in 2021 in Sydney, Australia, as a developer of psychedelic-derived therapeutics targeting mental health conditions. Improved treatments against selective serotonin reuptake inhibitors are provided through these drugs, addressing issues such as treatment-resistant depression, anxiety, and addiction. Operations focus on research and development within the biotechnology sector, with activities centered in Australia.
- Total Equity Funding$14.18M (USD)
in 3 rounds
- Latest Funding Round$8M (USD), Seed
Jun 2024
- InvestorsFocalpoint Partners
& 12 more
Products & Services of Psylo
Psylo offers a comprehensive portfolio of products and services, including Neuroplastogen Therapies and Pipeline Therapies.
Treatments enhancing neuroplasticity for brain disorders.
Advanced tools for developing neurological treatments.
Apps and channels of Psylo
its YouTube channel TEDx Talks has 26.7M subscribers and 30 videos.
Videos from Psylo
The most watched videos on Psylo's YouTube channel, TEDx Talks (26.7M subscribers). Click a video to play it here.
More on TEDx Talks.
Funding Insights of Psylo
Psylo has successfully raised a total of $14.18M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $8 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $14.18M
- Total Rounds 3
- Last Round Seed — $8M
- First Round $1.18M
(Oct 2021)
- Investors Count 13
All 3 funding rounds of Psylo with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2024 | $8M | Seed | – | Tenmile | |
| Oct 2022 | $5M | Seed | – | Main Sequence | |
| Oct 2021 | $1.18M | Seed | – | – |
13 investors in total: 12 institutional and 1 angel.
Investors in Psylo
Psylo has secured backing from 13 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Focalpoint Partners, Main Sequence and Lionheart Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are made in deep tech founders. | mseq.vc | Eveleigh, Australia | ||
A venture capital firm focused on transformative technologies is operated. | lionheart.vc | |||
Venture capital investments are made in health and technology sectors. | empath.vc | |||
| caramed.co.nz | ||||
Early-stage investments across multiple sectors are conducted by this firm. | possible.ventures | Munich, Germany | ||
Startmate is recognized as a leading startup accelerator in ANZ. | 2010 | startmate.com | Sydney, Australia | |
Health technology investments are made by Tenmile in Australia. | tenmile.com | Perth, Australia | ||
Investing in life sciences, AI, hardware, software, and health tech to advance human health, wellbeing, and performance. | 2021 | focalpointlp.com | Los Angeles, United States | |
Venture capital investing with a focus on diversity and inclusion in the ecosystem. | gaingels.com | |||
Limited information is provided about Palo Santo's activities. | palosanto.vc |
Investor details for Psylo
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Psylo
8 people are tracked at Psylo (5 in leadership, 3 in team).
| Name | Role | Group |
|---|---|---|
Josh Ismin | Co-Founder & CEO | Leadership |
Sam Banister | Co-Founder | Leadership |
🧪 Joshua Ismin | Co-founder, CEO | Leadership |
Lawrence P. (Larry) Wennogle, Ph.D. | Vice President Translational Research | Leadership |
Dilara Bahceci | Head of Communications | Leadership |
William Jorgensen | Lead Medicinal Chemist | Team |
Jin Tan | Computational And Medicinal Chemist | Team |
Lachlan Whish | Medicinal Chemist | Team |
Complete people profiles for Psylo
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Psylo
3 dated milestones of Psylo across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Psylo is founded.
- Funding First funding round of $1.2M.
- Funding Latest funding round, Seed, of $8.0M.
Web traffic of Psylo
Websites that share an audience with Psylo (psylo.bio).
Websites whose visitors overlap most with Psylo. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
hopkinspsychedelic.org | hopkinspsychedelic.org | 100% | #1,150,637 | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Psylo
Complete news archive for Psylo
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Psylo
Psylo was founded in 2021.
Psylo is headquartered in Sydney, Australia. It is registered at Sydney, New South Wales, Australia.
Josh Ismin is the CEO of Psylo, as recorded in our data. They have also founded this company.
Psylo is a funded company, having raised a total of $14.18M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1.18M, raised on Oct 2021.
Psylo was founded in 2021 in Sydney, Australia, as a developer of psychedelic-derived therapeutics targeting mental health conditions. Improved treatments against selective serotonin reuptake inhibitors are provided through these drugs, addressing issues such as treatment-resistant depression, anxiety, and addiction. Operations focus on research and development within the biotechnology sector, with activities centered in Australia.
Psylo offers Neuroplastogen Therapies and Pipeline Therapies.
Psylo has 13 investors. Key investors include Focalpoint Partners, Main Sequence, Lionheart Ventures, Negev Capital, and XEIA Venture Partners.
Psylo operates through Psylo Pty Ltd.